The patient was a 78-year-old woman in whom abdominal ultrasonography in a medical examination revealed dilatation of the main pancreatic duct. She, therefore, attended our hospital. Computed tomography (CT) \[[Figure 1](#F1){ref-type="fig"}\] and magnetic resonance imaging (MRI) revealed a mass lesion 10 mm in diameter in the pancreatic body. EUS-FNA was performed using a 25-gauge needle \[[Figure 2](#F2){ref-type="fig"}\], leading to a cytological diagnosis of adenocarcinoma. Distal pancreatectomy with splenectomy was followed by adjuvant systemic chemotherapy with S-1 for 1 year. Histopathological diagnosis of the surgically resected specimen was well-differentiated tubular adenocarcinoma (T3N0M0, Stage IIA), and there was no remnant of cancer in intraoperative or pathological findings. CT and/or MRI were repeated performed every 3--5 months until 18 months after resection showed no evidence of tumor recurrence or metastasis.

![Abdominal computed tomography: A mass lesion 10 mm in diameter in the pancreatic body (red arrow)](EUS-7-64-g001){#F1}

![EUS-FNA was performed using a 25-gauge needle](EUS-7-64-g002){#F2}

The patient was subsequently brought to the emergency center of our hospital with hematemesis 22 months later after surgery. Upper gastrointestinal endoscopy was performed, and a Borrmann type 2-like lesion with bleeding was detected in the posterior wall of the gastric body \[[Figure 3](#F3){ref-type="fig"}\] and confirmed as tubular adenocarcinoma from biopsy. CT revealed a gastric mass lesion located near the previous EUS-FNA puncture site \[[Figure 4](#F4){ref-type="fig"}\]. No evidence of any other metastatic lesions was apparent, and the patient was scheduled for partial gastrectomy.

![Upper gastrointestinal endoscopy image showing a Borrmann type 2-like lesion with bleeding in the posterior wall of the gastric body](EUS-7-64-g003){#F3}

![Abdominal computed tomography: A gastric mass lesion located near the previous EUS-FNA puncture site (yellow arrows)](EUS-7-64-g004){#F4}

Intraoperatively, peritoneal disseminated lesions were confirmed, so the patient only underwent local resection of the stomach. Histological examination of the resected specimen revealed well-to-moderately differentiated tubular adenocarcinoma located from the mucosa to the serosa, with no evidence of cancer cells on the serosal surface \[[Figure 5](#F5){ref-type="fig"}\]. *KRAS* mutation testing performed in both the pancreatic and gastric carcinomas demonstrated identical genetic alterations (G12V) in each specimen. The gastric lesion, therefore, indicated gastric wall implantation after the initial EUS-FNA for the pancreatic cancer.

![Histological examination of the resected specimen revealed well-to-moderately differentiated tubular adenocarcinoma located from the mucosa to the serosa, with no evidence of cancer cells on the serosal surface](EUS-7-64-g005){#F5}

Seeding of pancreatic cancer after EUS-FNA has seldom been reported. Ikezawa *et al*. reported that EUS-FNA for pancreatic cancer did not significantly increase the risk of peritoneal carcinomatosis.\[[@ref1]\] Needle tract seeding after surgery for pancreatic cancer has been reported in four patients since 2012.\[[@ref2][@ref3][@ref4][@ref5]\] In all these cases, the cancer was localized to the pancreatic body, preoperative transgastric EUS-FNA was performed, and 8--28 months after surgery, metastases were identified in the gastric wall. Preoperative transgastric EUS-FNA in patients with resectable pancreatic body and tail cancer thus needs to be reconsidered in collaborative discussion with surgeons.
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